|
HAT1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.00639996336582E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.90030000413577E-08 |
| Normal-vs-Stage2 |
5.43550000009496E-07 |
| Normal-vs-Stage3 |
4.54030000263117E-08 |
| Normal-vs-Stage4 |
7.58370000131237E-08 |
| Stage1-vs-Stage2 |
6.256300E-02 |
| Stage1-vs-Stage3 |
2.161800E-01 |
| Stage1-vs-Stage4 |
1.153760E-01 |
| Stage2-vs-Stage3 |
3.711400E-01 |
| Stage2-vs-Stage4 |
7.754400E-01 |
| Stage3-vs-Stage4 |
5.458200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.19380000224356E-09 |
| Normal-vs-AfricanAmerican |
1.801740E-02 |
| Normal-vs-Asian |
1.119280E-03 |
| Caucasian-vs-AfricanAmerican |
4.037000E-01 |
| Caucasian-vs-Asian |
3.226800E-01 |
| AfricanAmerican-vs-Asian |
9.408200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.26100052411493E-10 |
| Normal-vs-Female |
1.73340000131361E-08 |
| Male-vs-Female |
2.656300E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.57719999996464E-06 |
| Normal-vs-Age(41-60Yrs) |
9.83879999694182E-09 |
| Normal-vs-Age(61-80Yrs) |
7.54240003786322E-10 |
| Normal-vs-Age(81-100Yrs) |
6.357000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.082500E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.288200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.834000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.443400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.894600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.341200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.289400E-01 |
| Classical-VS-Follicular |
2.42359999998998E-05 |
| Classical-VS-Other |
2.790200E-02 |
| Classical-VS-Normal |
3.44320000000842E-06 |
| Tall-VS-Follicular |
1.371940E-02 |
| Tall-VS-Other |
4.466200E-02 |
| Tall-VS-Normal |
6.831300E-04 |
| Follicular-VS-Other |
6.224400E-01 |
| Follicular-VS-Normal |
5.72786262864611E-12 |
| Other-VS-Normal |
5.99019999999451E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.47869955064084E-10 |
| Normal-vs-N1 |
2.12290000001225E-06 |
| N0-vs-N1 |
5.529800E-01 |
|
|
